Literature DB >> 24252288

QTc compared to JTc for monitoring drug-induced repolarization changes in the setting of ventricular pacing.

Shane F Tsai1, Mahmoud Houmsse1, Barrah Dakhil1, Ralph Augostini1, John D Hummel1, Steven J Kalbfleisch1, Zhengou Liu1, Charles Love1, Troy Rhodes1, Jaret Tyler1, Raul Weiss1, Ismail Hamam1, Marshall Winner1, Emile G Daoud2.   

Abstract

BACKGROUND: QT prolongation is a risk factor for proarrhythmia when beginning antiarrhythmic drug therapy (AAD). However, there are no data regarding monitoring repolarization changes during a ventricular paced (VP) rhythm.
OBJECTIVE: The purpose of this study was to compare serial changes in corrected QT and JT intervals, during native conduction (NC) and VP rhythms when initiating Class III AADs.
METHODS: Twenty-two patients (73% men; mean age 65 ± 11 years) with an implantable device and with <10% VP were monitored during AAD initiation (16 sotalol, 6 dofetilide). QTc and JTc were measured from ECGs obtained during NC and VP at baseline (pre-AAD) and then after each AAD dose.
RESULTS: During AAD loading, mean QTc increased significantly during NC (431 ± 28 ms to 463 ± 33 ms, P = .002) but not with VP (520 ± 48 ms to 538 ± 45 ms, P = .07). Mean percent increase in peak QTc during NC was significantly greater than during VP (12% vs 7%, P = .003). In contrast, peak JTc during AAD loading was not significantly different between NC and VP (P = .67).
CONCLUSION: When initiating AAD, the change in QTc during VP does not correlate with the change in QTc during NC; thus, the VP QTc is inadequate for monitoring repolarization changes. However, VP JTc correlates well with JTc during NC. When initiating Class III AADs in patients with VP rhythms, the JTc, and not the QTc, interval is the useful marker for assessing repolarization.
© 2013 Heart Rhythm Society Published by Heart Rhythm Society All rights reserved.

Entities:  

Keywords:  Antiarrhythmic drug; Electrocardiography; JT interval; Pacing; QT interval; Repolarization

Mesh:

Substances:

Year:  2013        PMID: 24252288     DOI: 10.1016/j.hrthm.2013.11.017

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  6 in total

1.  Evaluation of Changes in Ventricular Repolarization Parameters in Morbidly Obese Patients Undergoing Bariatric Surgery.

Authors:  Ersin Ibisoglu; Deniz Dilan Naki Tekin; Filiz Kızılırmak; Saime Turgut Güneş; Bedrettin Boyraz; Yaşar Özdenkaya; Sinem Çakal; Beytullah Çakal; Ümeyir Savur; Aslan Erdoğan; Fatih Erkam Olgun; H Murat Güneş
Journal:  Obes Surg       Date:  2021-04-15       Impact factor: 4.129

2.  Risk of Mortality Associated With QT and JT Intervals at Different Levels of QRS Duration (from the Third National Health and Nutrition Examination Survey).

Authors:  Muhammad A Zulqarnain; Waqas T Qureshi; Wesley T O'Neal; Amit J Shah; Elsayed Z Soliman
Journal:  Am J Cardiol       Date:  2015-04-06       Impact factor: 2.778

3.  Arrhythmogenic drugs can amplify spatial heterogeneities in the electrical restitution in perfused guinea-pig heart: An evidence from assessments of monophasic action potential durations and JT intervals.

Authors:  Oleg E Osadchii
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

4.  Value of the New Spline QTc Formula in Adjusting for Pacing-Induced Changes in Heart Rate.

Authors:  Hirmand Nouraei; Matthew Bennett; Simon Rabkin
Journal:  Cardiol Res Pract       Date:  2018-04-01       Impact factor: 1.866

Review 5.  Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives.

Authors:  Jialin Duan; Jingwen Tao; Maocai Zhai; Chengpeng Li; Ning Zhou; Jiagao Lv; Lin Wang; Li Lin; Rong Bai
Journal:  Oncotarget       Date:  2018-05-22

6.  Assessment of QT and JT Intervals in Patients With Left Bundle Branch Block.

Authors:  Peyman Tabatabaei; Ala Keikhavani; Majid Haghjoo; Amirfarjam Fazelifar; Zahra Emkanjoo; Mahbobeh Zeighami; Hooman Bakhshandeh; Behshid Ghadrdoost; Abolfath Alizadeh
Journal:  Res Cardiovasc Med       Date:  2016-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.